In this episode, a multidisciplinary panel of pulmonology, thoracic surgery and oncology experts discusses real-world lung nodule cases and how noninvasive CyPath® Lung testing can help refine risk stratification. The panel explores when testing may support decisions to pursue biopsy, when a negative result may help avoid unnecessary invasive procedures, and how multidisciplinary collaboration can improve the management of patients with indeterminate lung nodules. The experts also look ahead to the evolving role of noninvasive testing in lung nodule management.

In this episode, a multidisciplinary panel - an interventional pulmonologist, thoracic surgeon, and medical oncologist - explores the growing challenge of indeterminate lung nodules in high-risk patients. The experts discuss the limitations of current risk-stratification approaches and how CyPath® Lung, a noninvasive sputum-based test, can provide objective information to help clinicians better assess the likelihood of malignancy and guide decisions about follow-up, surveillance, or biopsy.

In this episode, the pulmonologists participating in a roundtable discussion go beyond the challenges of pulmonary nodule management to discuss how CyPath® Lung is being integrated into real-world clinical workflows. The panel explores patient anxiety and stigma, when to biopsy and when not to, and how a noninvasive sputum-based test can risk stratify and help guide next steps for patients with indeterminate pulmonary nodules.

The discussion also takes a deeper look at the science behind CyPath® Lung and offers compelling patient cases—including a smoker ultimately diagnosed with Stage I lung cancer and a heart transplant candidate with a difficult-to-access pulmonary nodule.